ABSTRACT Interests in intracellular peptide delivery have continued to grow, significantly fueled by the importance of peptides and their mimetics in modern cell biology and pharmaceutical industry. However, efficient intracellular delivery of membrane-impermeable peptides of different polarities remains a challenging task. In this study, we develop a general and robust strategy for intracellular peptide delivery by using a boronic acid-rich dendrimer. The designed material is capable of transporting peptides with different polarities and charge properties into the cytosol of various cell lines without inducing additional cytotoxicity. The transduction efficacy and proteolytic stability of cargo peptides delivered by the boronic acid-rich dendrimer are much superior to peptides conjugated with cell penetrant peptides such as octaarginine. In addition, the bioactivities of pro-apoptotic peptides are maintained after intracellular delivery. This study provides a versatile and robust platform for the intracellular delivery of membrane-impermeable peptides.
INTRODUCTION
Peptides are short amino acid sequences that could maintain the same or partial biological functions of natural proteins, and have drawn great interests as promising tools in molecular cell biology or drug candidates in clinical trials [1] [2] [3] [4] . They were reported to play critical roles in cell adhesive and penetrating, tumor targeting, signal transduction, homeostasis and reproduction, cell apoptosis, nuclear localization, and immunity regulation, i.e., induction of T-cell response against pathogens [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Compared with traditional small molecule drugs, peptide-based therapeutics are particularly preferred due to higher specificity towards drug targets, higher safety such as limited adverse effects and immunogenicity, and faster clinical development [17] . As a result, the number of FDA-approved peptide-based drugs is increasing in recent years [5] . The current peptide drugs mainly exert their effect on extracellular membrane targets like ion channels and receptors existing on cell membranes, where they exert their bioactivity through intracellular signaling cascades [1] . Although peptides hold great promise in modern pharmacy, they usually cannot reach intracellular protein targets due to limited membrane-permeability of most peptides [18] . New strategies that are available for the intracellular delivery of membrane-impermeable peptides are highly desired [19] .
To facilitate the intracellular delivery, cargo peptides were usually fused with cell penetrant peptides (CPPs), i.e., the transactivator of transcription (TAT) of HIV and octaarginine R8 [20] . The CPP-tagged peptides could translocate cell membranes predominantly via endocytic pathways [21, 22] . Alternatively, the cargo peptides were linked to an anthrax lethal factor, which could further bind to protective antigens on cell surface to initiate endocytosis [23] . However, the strategies always require a high dose of peptides to achieve moderate transduction efficiency due to the entrapment of cargoes within endolysosomes in the cells. To address this issue, various peptide delivery carriers such as amphiphilic chemicals, lipid nanoparticles, polymers, nanogels and inorganic nanoparticles were developed [5, 17, [24] [25] [26] [27] . For example, a host- [2] rotaxane containing both cationic arginine and aromatic moieties to host cargo peptides with various polarities was developed, and the complex could enter cells via passive translocation [18] . In a separate study, an endosomolytic anionic polymer was complexed with cationic cargo peptides via electrostatic interactions to form nanoparticles for efficient cytosolic delivery [17] . Alter-natively, peptides to be delivered were incorporated into activatable protein nanoparticles formed through coiledcoil dimerization of polypeptides, and the cargo peptides can be released from the nanoparticles triggered by environment specific enzymes [28] . Very recently, our laboratory developed several cationic polymers such as guanidium-rich polymers and fluoropolymers for efficient intracellular peptide and protein delivery [24, [29] [30] [31] [32] [33] [34] [35] . Despite these advances, the development of an efficient material for cytosolic delivery of peptides with various polarities and charge properties is still a major challenge in this emerging area.
For peptides with short amino acid sequences, there are limited binding sites for the polymeric carriers. In addition, the peptides usually have distinct polarities and charge properties, so it is difficult for peptides to be delivered via ionic interactions just like nucleic acids [36] [37] [38] . Here, we developed a boronic acid-rich cationic dendrimer for efficient internalization of peptides into different cell lines. Boronic acid is an electron deficient group which could interact with the electron-rich residues on the peptides such as amine and hydroxyl groups via coordination bonding between Lewis acid and base [39] [40] [41] [42] [43] . In addition, the cationic dendrimer could bind with anionic groups of cargo peptides via ionic interactions. The combination of these interacting forces facilitates the binding of cargo peptides to the designed material for intracellular peptide delivery. Besides peptide binding, boronic acid-rich materials were reported to successfully circumvent numerous extracellular and intracellular barriers existing in intracellular delivery of biomacromolecules, such as cell targeting, cellular uptake, endosomal escape and cytosolic cargo release [39, [44] [45] [46] [47] [48] . Based on these rationales, the designed boronic acid-rich dendrimer was expected to have high intracellular translocation efficiency towards peptides with various polarities and isoelectric points (pIs).
EXPERIMENTAL SECTION

Materials
Generation 5 polyamidoamine dendrimer (G5 PAMAM) was bought from Dendritech (Midland, USA). Peptides and fluorescein isothiocyanate (FITC)-labelled peptides were synthesized by GL Biochem. (China). 4-(Bromomethyl)phenylboronic acid was obtained from Macklin Biochem. (China). Rhodamine B isothiocyanate (RBITC), genistein, chlorpromazine (CPZ), methyl-β-cyclodextrin (MβCD) and Hoechst 33342 were bought from SigmaAldrich (USA). Ethylisopropylamiloride (EIPA) was purchased from MedChem Express (USA). Lactate dehydrogenase (LDH) assay kit, annexin V-FITC apoptosis kit, Lysotracker Red were provided by Beyotime (China). Trypsin was purchased from Macklin (China).
Synthesis of BDP and RBITC-labeled BDP
4-(Bromomethyl)phenylboronic acid (128 μmol) was reacted with dendrimer at a molar ratio of 128:1 in dimethyl sulfoxide at 70°C for 24 h followed by dialysis and freeze-drying. The purified material was characterized by 1 H NMR spectroscopy (Bruker, 500 MHz). For synthesis of RBITC-labeled boronic acid-decorated dendrimer (BDP), 0.25 μmol BDP was reacted with 0.75 μmol RBITC in deionized water for 24 h followed by dialysis and freeze-drying to obtain BDP-RBITC.
Preparation and characterization of BDP/peptide complexes BDP was added into peptide solutions at various mass ratios. The complex solutions were incubated for 30 min. The formed particles were characterized by dynamic light scattering (Malvern, UK) and transmission electron microscope (HITACHI, Japan), respectively. Polymer/peptide binding and in vitro peptide release were tested by fluorescence resonance energy transfer (FRET). BDP-RBITC was mixed with peptide-FITC (1.5:1, mass ratio) and incubated for 30 min. The fluorescence spectrum of the sample was tested by fluorescence spectrophotometer (F4500, HITACHI, Japan). Peptide binding ratios of BDP were tested as follows: the BDP/peptide complexes were incubated for 30 min, and then diluted with distilled water or cell culture buffer (cell culture medium without phenol red). The solutions were centrifuged at 12,000 r min −1 for 20 min, and the concentrations of peptides in the supernatant were measured. The corresponding peptides without addition of polymer were tested as controls. The peptide binding ratio (%) of BDP to each peptide was calculated as follows: (C control − C BDP/peptide complexes )/C control ×100, where C represents the concentrations of peptides in the corresponding supernatant. For in vitro peptide release, the BDP-RBITC/ peptide-FITC complexes were added with a competitor protein bovine serum albumin (0.5 mg mL −1 ) and then the fluorescence spectrum of the yielding mixture solution was measured. 
Cell culture and cytosolic peptide delivery
LDH release and apoptosis assay
The HeLa cells were seeded in 96-well plate (~5000 each well) overnight till 50% confluence, and then treated with the DBP/peptide complexes or control peptides for 4 h in the absence of serum. Then, the medium was removed and replenished with 250 μL medium (10% FBS) and cultured for 20 h. LDH release from the treated cells was tested according to the manufacturer's protocol (Beyotime, China). For the apoptosis assay, cells were cultured with the formulations as described above, then stained by the FITC-Annexin V apoptosis kit (Beyotime, China) and analyzed by flow cytometry. For cell membrane leakage assay, HeLa cells were cultured with the complexes as described above. After being washed with phosphate buffer saline (PBS) thrice, the treated cells were cultured with 10 μmol L −1 calcein for 10 min, and then washed with PBS thrice before observation by confocal microscopy.
Internalization mechanism
The HeLa cells were pretreated with inhibitors such as EIPA (30 μg mL −1 ), genistein (189 μg mL −1 ), CPZ (7 μg mL −1 ) and MβCD (13 mg mL
) for 1 h before the addition of complexes. Fluorescence of treated cells was analyzed by flow cytometry and confocal microscopy. Cells treated with BDP/peptide complex at 37°C without any inhibitor were tested as control (100% fluorescence intensity). The intracellular peptide delivery experiment was also conducted at 4°C to reveal the role of energy during internalization. To monitor intracellular localization of the cargo peptides, cells were treated with BDP/ peptide complex for 2 and 4 h, respectively. The acidic compartments and nuclei of the treated cells were stained by Lysotracker red (200 nmol L −1 ) and Hoechst 33342 (2.5 μg mL −1 ) at 37°C for 20 and 10 min, respectively.
Then the treated cells were washed with PBS thrice before being observed by confocal microscopy.
Proteolytic stability BDP (6 μg) was mixed with peptides at a weight ratio of 1.5:1, added with 50 μL HEPES buffer and further incubated for 0.5 h. The complex was treated with 0.2 μg trypsin for 2 h. After that, the complex solution was diluted with 250 μL medium without FBS and incubated with the cells. After incubation for 4 h, the medium was removed and the treated cells were washed with PBS thrice. The internalized peptides were measured by flow cytometry. R8-or TAT-conjugated peptides were tested as described above.
Data analysis
The data were presented as mean±SD (n=3 for the peptide delivery experiments, and n=5 for MTT assay 
RESULTS AND DISCUSSION
The dendrimer was conjugated with 4-(bromomethyl) phenylboronic acid by a facile chemistry. According to the 1 H NMR result (Fig. S1 ), a BDP with 68 phenylboronic acid modified on each dendrimer was obtained (Fig. 1a) . Peptides with various polarities and pIs were labeled with FITC at the N-terminal during synthesis to monitor the intracellular peptide delivery (Fig. 1b) . BDP was complexed with the cargo peptides in Fig. 1b by gently mixing the two species together at a weight ratio of 1.5:1 (polymer to peptide). All the peptides alone showed poor translocation efficiency on HeLa cells; however, the presence of BDP significantly improved the translocation efficiencies of the investigated peptides as confirmed by flow cytometry analysis (Fig. 1c) and confocal images (Fig. 1d) . The addition of trypan blue, a membrane-impermeable fluorescence quencher, only slightly decreased the fluorescence on the treated cells (Fig. S2) , which suggested the internalization of cargo peptides by the treated cells. The peptides P2, P4 and P5 with distinct charge properties and hydrophobicities were selected as model peptides in further studies.
As shown in Fig. 2a , the peptide delivery efficacies of BDP are comparable or much superior to those of CPPtagged peptides such as TAT-and R8-conjugated peptides. The binding of cargo peptides with BDP was confirmed by FRET (Fig. S3) , dynamic light scattering and transmission electron microscopy analyses (Fig. S4) . The binding ratios of BDP to the peptides were around or above 60% in distilled water, and diluting with cell culture buffer only slightly reduced the peptide binding ratios of BDP (Fig. S5) . The successful binding of cargo peptides with BDP not only facilitates their membrane transporting but also protects them from enzymatic degradation. To confirm this hypothesis, TAT-and R8-conjugated peptides and BDP/peptide complexes were pre-incubated with trypsin for 2 h, and then used to treat HeLa cells for 4 h before being measured by flow cytometry. The fluorescence intensities of cells treated with R8-and TAT-conjugated peptides were significantly decreased in the presence of trypsin, while those with BDP/peptide complexes were slightly changed under the same condition (Fig. 2b, c and Fig. S6 ). These results clearly demonstrated the excellent proteolytic stability of BDP/ peptide complexes, which is critical for maintaining the bioactivity of peptides during intracellular delivery. Moreover, the carrier BDP shows minimal cytotoxicity at various concentrations (Fig. S7) . Further studies suggested that the internalization of BDP/P2 complexes by HeLa cells was energy-dependent and involved with multiple pathways including macropinocytosis-, caveolindependent endocytosis and clathrin-dependent endocytosis (Fig. 3a, b) . Boronic acid-rich polymers were reported to circumvent multiple intracellular barriers existing during gene and protein delivery [39, 44, [49] [50] [51] [52] . The internalized BDP/peptide complexes showed efficient endosomal escape after 4 h incubation with the cells (Fig.  S8) . The bound peptides could be released from BDP in the presence of abundant proteins in the cytoplasm (Fig.  S9) . We further investigated the effects of peptide dosage and incubation time on the intracellular delivery efficacy. As shown in Fig. S10 , fluorescence intensity of the BDP/ P2 complex-treated cells increased in proportion to peptide dosage, and the internalization was saturated at 8 μg peptide. In addition, the intracellular peptide delivery by BDP also depended on the incubation time. The fluorescence intensity of cells increased with incubation time, and was saturated when the incubation time reached 8 h. Besides HeLa cells, BDP was effective when delivering P2 into various cells such as HEK293, MDA-MB-231, MCF-7, BAT, and iWAT (Fig. 3c) .
We further investigated whether the bioactivity of cargo peptides could be maintained after intracellular delivery by BDP. A membrane-impermeable peptide ACSAG (AG5) with potential pro-apoptotic activity was used as the model peptide to test the feasibility of BDP in the delivery of bioactive peptides [53, 54] . As shown in Fig. 4a , b, AG5-FITC showed minimal cellular uptake; however, the BDP/AG5-FITC complex exhibited dramatically in- , respectively. The molar concentrations of R8-and TAT-conjugated peptides were equal to those of P2, P4 and P5 in the BDP complexes, respectively. creased cellular internalization, which was much higher than that of R8-conjugated AG5-FITC. We further tested the anti-cancer activities of AG5, R8-AG5 and BDP/AG5 on HeLa cells. As shown in Fig. 4c -e, BDP/AG5 complex caused much increased membrane leakage, cell apoptosis and death on HeLa cells in comparison with AG5 and R8-AG5, and the toxicity of complex was not caused by the carrier BDP. The peptide CWMSPRHLGTC (CC11) is a cyclic pro-apoptotic peptide that can block the protein kinase CK2 phosphorylation and induce apoptosis in cancer cells [55] . As shown in Fig. 5a , b, FITC-labeled CC11 itself showed poor membrane permeability into HeLa cells, while BDP could efficiently translocate the peptide into cytosol of the treated cells. More importantly, the cancer cells treated with BDP/CC11 complex showed significant apoptosis, while CC11 and BDP only induced minimal apoptosis in the treated cells (Fig. 5c, d ). These results suggest that BDP-mediated intracellular peptide delivery can preserve the bioactivity of cargo peptides.
CONCLUSIONS
In summary, the designed material BDP permits the efficient translocation of cargo peptides with various properties across plasma membranes to exert their functions inside the cells. The delivered cargo peptides maintain their bioactivities after intracellular release. In addition, the designed material shows low toxicity on treated cells. The current study provides an efficient and robust strategy to design vectors for intracellular peptide delivery. 
